Pre-made Crizanlizumab benchmark antibody ( Whole mAb, anti-SELP therapeutic antibody, Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-123
Pre-Made Crizanlizumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Crizanlizumab, sold under the brand name Adakveo, is a monoclonal antibody medication developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Crizanlizumab biosimilar, Whole mAb, Anti-SELP Antibody: Anti-CD62/CD62P/GMP140/GRMP/LECAM3/PADGEM/PSEL therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Approved||Vaso-occlusive crisis|